This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.
ST-segment-elevation myocardial infarction (STEMI) is most commonly caused by rupture or erosion of an atherosclerotic plaque, resulting in acute occlusion of the coronary artery, and the preferred reperfusion strategy is primary percutaneous coronary intervention (PCI). The no-reflow phenomenon is one of the most common causes of adverse cardiovascular events in patients STEMI. In recent years, mechanical or pharmacological treatment strategies including adjunctive administration of glycoprotein IIb/IIIa inhibitors (GPI) have been proposed in patients with STEMI.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
Patients will receive intracoronary tirofiban (Aggrastat®) (25 mg/kg).
Patients will receive intracoronary saline 0.9% solution as a control group.
Kafrelsheikh University
Kafr ash Shaykh, Kafrelsheikh, Egypt
RECRUITINGBlood stream
Blood stream in coronary artery before and after treatment, including Thrombolysis in Myocardial Infarction (TIMI) flow grade in IRAs, coronary blood flow will be calculated with TIMI frame count method.
Time frame: After treatment (Up to 15 minutes)
Incidence of major adverse cardiac events
Incidence of major adverse cardiac events were recorded.
Time frame: After treatment (Up to 30 days)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.